Search Site
Cancer Genetics

ONCOSEQ DNALAB LIQUID BIOPSY PANEL

ONCOSEQ DNALAB LIQUID BIOPSY PANEL

( 28 GENE )

Cancer is one of the most important and unfortunately increasing health problems today. With the increase in genetic studies on etiology, the contribution to early diagnosis and treatment protocols is also increasing. For this reason, in many cases diagnosed with cancer recently, genetic tests are planned from peripheral blood or cancer tissue, and the follow-up and follow-up of the patients are determined by the contribution of the genetic results to the integrity.
The biggest problem with cancer is that no exact cure has been found. Although mutations in the genetic structure in cancer cases may vary from patient to patient, they may also change over time in the same patient. Due to this dynamic etiology, treatment planning becomes difficult. Resistance to the relevant cancer drug may also be observed in individuals carrying some mutations. In order to detect all genetic changes and dynamic changes, the latest genetic technology (liquid biopsy) targets the tumor cell genome circulating in the peripheral blood of the patient.

  • AKTl*
  • ALK*
  • AR*
  • BRAF*
  • CTNNB1*
  • DDR2*
  • EGFR*
  • ERBB2*
  • ESR1*
  • FGFR1*
  • HRAS*
  • IDH1*
  • KIT*
  • KRAS*
  • MAP2K1*
  • MAP2K2*
  • MET*
  • MTOR*
  • NRAS*
  • NTRK1*
  • NTRK3*
  • PDGFRA*
  • PIK3CA*
  • RET*
  • ROS1*
  • SMAD4*
  • TP53

*SNV/indel analysis is performed on marked genes

WHY CHOOSE CENTOGENE?
  • Test:
    Liquid Biopsy Test
  • Method:
    Next Generation Sequencing
  • Analysis Time:
    14-21 Days
  • Sample Type:
    cfDNA
  • Sample Type:
    FFPE (Tissue), Blood (EDTA), cfDNA
  • Storage Conditions:
    1 week at +4 C
  • Transport Conditions:
    The same day; At room temperature
  • Rejection Criteria:
    Hemolyzed, Lipemic, Icteric samples are not accepted
DNA Image

Liquid biopsy is a new generation test based on the analysis of circulating tumor cells (CTC) in the person’s peripheral blood, which is very important in early diagnosis and evaluation of response to treatment. Tumor cells circulating in the blood; It consists of tumor DNA (ctDNA), cell-free RNA (cfRNA), tumor-prone platelets and exosomes.

Cell-free DNA (cfDNA): Abnormally proliferating cells trigger cell death (necrosis and apoptosis) and cfDNAs leave the tumor and enter the circulation. By targeting these cfDNAs, many cancer-related genes are identified by next-generation sequencing (NGS) method.ri ile analiz edilebilir.

The concept of “targeted smart drug”, which has been on the agenda in recent years, targets mutations in the gene(s) and determines the treatment decision. Molecular analyzes performed only on tumor tissue may not be sufficient and are invasive procedures. With the diagnostic acceptance of liquid biopsy, a rapid contribution to the unknown was made. Hundreds of genes can be evaluated simultaneously (cancer gene panels) in terms of genetic etiology, and the diagnostic accuracy rate increases. It also sheds light on evaluating the effectiveness of immunotherapy, another popular cancer treatment method. Because genetic tests for cancer treatment, such as tumor mutation burden (TMB) and microsatellite instability (MSI), can be easily detected by liquid biopsy.

DNA Image
DNA Image

Advantages;

  • It increases the success of treatment as it provides early diagnosis.
  • Tumor tissue may not be obtained by methods such as tissue needle biopsy (such as brain biopsy). In these cases, it is diagnostic.
  • It takes a long time for the histopathological diagnosis to be completed. It gives quicker insight into the diagnosis.
  • It is not an invasive method.

Discover Your Genetic Heritage

You can contact us to get information about our genetic tests, consultancy services and more.

Contact Us

ONCOSEQ DNALAB (Cancer Genetics)

PRIMIS Non-Invasive Prenatal Test

Preimplantation Genetic Diagnosis (PGD)

Whole Exome Sequencing

Clinical Exome Sequencing

Rare Diseases

Carrier Panels - SMARİS